SCHEMBL3369422

SCHEMBL3369422

CCCC1CC1(N)C(=O)OC

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 4/20 0.36
GRM5 P41594 1/20 0.36
GRM1 Q13255 1/20 0.36
GRM4 Q14833 5/20 0.33
GRM8 O00222 4/20 0.33
GRM6 O15303 4/20 0.33
CYP3A4 P08684 3/20 0.32
TSHR P16473 2/20 0.32
GRM3 Q14832 2/20 0.31
ARG1 P05089 1/20 0.31
LMNA P02545 1/20 0.30
TP53 P04637 1/20 0.30
MAPT P10636 1/20 0.30
MAPK1 P28482 1/20 0.30
HTT P42858 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13757812 1.00 GRM2 (0.36) GRM2GRM5GRM1GRM4GRM8
Hydrochloric Acid SCHEMBL3375949 0.98 GRM2 (0.35) GRM2GRM5GRM1GRM4GRM8
SCHEMBL28747535 0.89 ARG1 (0.35) GRM2GRM5GRM1GRM4GRM8
SCHEMBL29681754 0.89 ARG1 (0.35) GRM2GRM5GRM1GRM4GRM8
SCHEMBL3370713 0.85 GRM2 (0.36) GRM2GRM5GRM1GRM4GRM8
SCHEMBL13757783 0.85 GRM2 (0.36) GRM2GRM5GRM1GRM4GRM8
SCHEMBL3238992 0.85 GRM2 (0.38) GRM2GRM5GRM1GRM4GRM8
SCHEMBL10272013 0.85 GRM2 (0.38) GRM2GRM5GRM1GRM4GRM8
SCHEMBL16575073 0.85 GRM2 (0.38) GRM2GRM5GRM1GRM4GRM8
SCHEMBL2487735 0.85 GRM2 (0.38) GRM2GRM5GRM1GRM4GRM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8809267-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2014-08-19 US disclosed
US-20140051626-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2014-02-20 US disclosed
US-8513186-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2013-08-20 US disclosed
EP-2162432-A2 ANTIVIRAL COMPOUNDS Gilead Sciences, Inc. (US) 2010-03-17 EP disclosed
US-20090186869-A1 Antiviral compounds GILEAD SCIENCES, INC. (US) 2009-07-23 US disclosed
WO-2009005677-A2 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2009-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186869-A1 Antiviral compounds MAVS, EIF2AK2, ZC3HAV1 GRM2 4537/4885GRM5 3890/4885GRM1 4079/4885
US-20140051626-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 GRM2 4537/4885GRM5 3890/4885GRM1 4079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.